Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K

Hepion Pharmaceuticals, Inc.

Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
Annual base salary $350,000; $50,000 deferred until equity financing ≥$3M, termination, or change of control.
Annual cash bonus target 35% of base salary based on Board-set goals.
Change-of-control bonus: 3% of enterprise value if ≥$5M.
Severance: 6 months base plus bonus upon termination without cause or good reason; equity acceleration provisions.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.